Similar articles for PMID: 30281999

Year	Number of Results
1994	3
1995	3
1996	1
1998	7
1999	4
2000	1
2001	4
2002	4
2003	4
2004	7
2005	12
2006	7
2007	6
2008	9
2009	7
2010	9
2011	4
2012	7
2013	12
2014	9
2015	14
2016	10
2017	14
2018	16
2019	19
2020	16
2021	18
2022	12
2023	8
2024	2

1

Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.

Li HQ, Xu JY, Gao YY, Jin L. Li HQ, et al. Pharmacol Res. 2018 Nov;137:135-147. doi: 10.1016/j.phrs.2018.09.030. Epub 2018 Sep 30. Pharmacol Res. 2018. PMID: 30281999

2

Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics.

Thentu JB, Nirogi R, Bhyrapuneni G, Ajjala DR, Aleti RR, Palacharla RC. Thentu JB, et al. J Pharmacol Toxicol Methods. 2017 May-Jun;85:22-28. doi: 10.1016/j.vascn.2017.01.001. Epub 2017 Jan 4. J Pharmacol Toxicol Methods. 2017. PMID: 28063918

3

Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.

Kapur S, Zipursky RB, Remington G. Kapur S, et al. Am J Psychiatry. 1999 Feb;156(2):286-93. doi: 10.1176/ajp.156.2.286. Am J Psychiatry. 1999. PMID: 9989565

4

Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.

Kaur G, Gupta D, Chavan BS, Sinhmar V, Prasad R, Tripathi A, Garg PD, Gupta R, Khurana H, Gautam S, Margoob MA, Aneja J. Kaur G, et al. Asian J Psychiatr. 2017 Oct;29:174-182. doi: 10.1016/j.ajp.2017.07.026. Epub 2017 Jul 6. Asian J Psychiatr. 2017. PMID: 28692863

5

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC. Graff-Guerrero A, et al. JAMA Psychiatry. 2015 Sep;72(9):927-34. doi: 10.1001/jamapsychiatry.2015.0891. JAMA Psychiatry. 2015. PMID: 26131622

6

Risperidone-related weight gain: genetic and nongenetic predictors.

Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, Chang WH. Lane HY, et al. J Clin Psychopharmacol. 2006 Apr;26(2):128-34. doi: 10.1097/01.jcp.0000203196.65710.2b. J Clin Psychopharmacol. 2006. PMID: 16633140 Clinical Trial.

7

Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Nyberg S, et al. Am J Psychiatry. 1999 Jun;156(6):869-75. doi: 10.1176/ajp.156.6.869. Am J Psychiatry. 1999. PMID: 10360125 Clinical Trial.

8

Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.

Wong YC, Centanni M, de Lange ECM. Wong YC, et al. J Clin Pharmacol. 2019 May;59(5):731-747. doi: 10.1002/jcph.1365. Epub 2019 Jan 24. J Clin Pharmacol. 2019. PMID: 30676661 Free PMC article.

9

Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.

Olsen CK, Brennum LT, Kreilgaard M. Olsen CK, et al. Eur J Pharmacol. 2008 Apr 28;584(2-3):318-27. doi: 10.1016/j.ejphar.2008.02.005. Epub 2008 Feb 12. Eur J Pharmacol. 2008. PMID: 18325493

10

Risperidone plasma levels, clinical response and side-effects.

Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Müller-Arends A, Weber K, Zach J, Müller N, Möller HJ. Riedel M, et al. Eur Arch Psychiatry Clin Neurosci. 2005 Aug;255(4):261-8. doi: 10.1007/s00406-004-0556-4. Epub 2004 Nov 29. Eur Arch Psychiatry Clin Neurosci. 2005. PMID: 15565299 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

216 results

Results by year